 Adamis Pharmaceuticals is preparing to launch a Phase IIIII study with TEMPOL in COVID-19 patients. The NIH recently reported that they found TEMPOL inhibits viral replication. I believe TEMPOL could be a leading COVID-19 therapeutic that can be employed at all stages of the infection. I provide some background on TEMPOL. 